Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Oct 2012 07:00

RNS Number : 7945P
Fastnet Oil & Gas PLC
30 October 2012
 



30 October 2012

Fastnet Oil & Gas plc

 

Directorate Change

 

Appointment of Carol Law, former Anadarko Exploration Manager as Executive Director of Fastnet

Fastnet Oil and Gas plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI) the newly listed E&P company focussed on near term exploration acreage in the Celtic Sea and Africa, is pleased to announce the appointment of Carol Law to the Board as an Executive Director, with immediate effect.

 

Carol is a geologist by training and has over 28 years' experience in the petroleum industry. In that time, she has been active in exploration management, exploration geology, research, and consulting in a variety of geological settings worldwide, having been involved in exploration activities in more than 40 countries. During her career, Carol has been a member of teams responsible for discoveries in Mozambique (Rovuma Gas), Ghana (Jubilee), Brazil (multiple Campos Basin discoveries), Alaska (Nikaitchuq), China (Bohai Bay) plus Angola, the Gulf of Mexico and others. Most recently Carol was Exploration Manager - East Africa & Caribbean for Anadarko Petroleum Corporation and was responsible for the team that discovered the Prosperidade gas complex in Rovuma Area 1, offshore Mozambique.

 

In addition, Carol was a member of the technical team and later Exploration Manager - West Africa, China, and Alaska for Kerr McGee Oil & Gas. Technical and managerial responsibility amongst her portfolio included offshore Morocco, including what is now the Foum Assaka block held by Fastnet and Kosmos Energy. Carol's Kerr McGee experience also included working in partnership with Kosmos Energy in offshore southern Morocco, Benin, and Ghana.

 

Carol will retain outside interests but, as an Executive Director of Fastnet, a significant portion of her time will be spent working with the Fastnet senior management team to develop and execute an oil and gas strategy focused on near term growth. She will also work with the technical teams and partners, de-risking and high-grading existing opportunities to create shareholder value. As Carol is based in Houston, Texas, she will provide Fastnet excellent access to the global oil and gas sector and, in addition, her proximity to Dallas based Kosmos Energy (Fastnet's partner in Morocco) will enable her to work closely with their Morocco team to progress that opportunity.

 

Michael Nolan non-executive director of Fastnet and Finance Director of Cove Energy plc, commented: 

"At Cove, we worked very closely with Carol for over three years, starting with the hugely successful rank wildcat drilling campaign in the Rovuma Area 1 partnership in 2009, which has delivered the enormous gas resources in Mozambique. She is due enormous credit for her commitment to and belief in this project and her role in this world class discovery was very significant. I have great confidence in her ability to be a great addition to the Fastnet team."

 

Cathal Friel, Non-Executive Chairman of Fastnet commented:

"We are delighted to welcome Carol to the Fastnet senior management team; with her exploration track record offshore Africa and her working knowledge of the Foum Assaka block in Morocco, Carol's experience will be of vital importance as we seek to mature the Moroccan acreage towards exploratory drilling.

 

"Beyond this, Carol's contact base and reputation will enhance the Company's ability to secure new exploration prospects, in line with our stated strategy at the time of our IPO, of exposing shareholders to near term, high impact exploration opportunities."

 

- Ends -

 

 

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Non-Executive Chairman

Steve Staley, CEO

+353 (1) 644 0007

Shore Capital

(Nominated Adviser & Joint Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

Davy

(ESM Adviser & Joint Broker)

John Frain

Brian Garrahy

Roland French

 

+353 (1) 679 6363

FTI Consulting

Edward Westropp/Jess Allum

+44 (0) 207 831 3113

 

 

Carol Ann Law (aged 52) currently holds, and has held (including all appointments during the five years preceding the date of this announcement), the following directorships and partnerships, other than of the Company:

 Current Directorships

None

Past Directorships

None

There are no other matters which are required to be announced under Rule 17 or Schedule Two paragraph (g) of the AIM rules.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEDKLFLLBFXFBE
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.